Official Title
Ensayo clínico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilácticas o terapéuticas de Bemiparina en Pacientes Con COVID-19
Brief Summary

Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.

Unknown status
COVID-19

Drug: Bemiparin sodium

Prophilactic vs full-dose for 10 days
Other Name: Hibor

Eligibility Criteria

Inclusion Criteria:

- Age (equal or more than 18 yo)

- Hospitalization at conventional wards due to COVID-19 related mild or moderate
pneumonia (CURB65<3 points; Sat. O2>90%)

- 3-4 points according to the WHO ordinal scale.

- Confirmed COVID-19 (PCR or other validated test)

- D-dimer >500 ng/mL

- Sign of informed consent

- The patient is able, according to investigator's opinion, to deal with all the
requirements of the clinical trial.

Exclusion Criteria:

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Spain
Locations

Hospital Rey Juan Carlos
Móstoles, Madrid, Spain

Clinica Universidad de Navarra
Pamplona, Navarra, Spain

Hospital Clinic
Barcelona, Spain

Hospital Sant Pau
Barcelona, Spain

Hospital Universitario Bellvitge
L'Hospitalet De Llobregat, Spain

Fundación Jiménez Díaz
Madrid, Spain

Hospital Clínico San carlos
Madrid, Spain

Hospital Universitario La Paz
Madrid, Spain

Complejo Hospitalario de Navarra
Pamplona, Spain

Hospital Universitario de Salamanca
Salamanca, Spain

Complejo Hospitalario de Toledo
Toledo, Spain

Hospital Universitario Río Hortega
Valladolid, Spain

Contacts

Ramon Lecumberri, MD, PhD
+34 948296397
rlecumber@unav.es

Ramon Lecumberri, Md, PhD, Principal Investigator
University of Navarra

Clinica Universidad de Navarra, Universidad de Navarra
NCT Number
MeSH Terms
COVID-19
Bemiparin